<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LEVOFLOXACIN- levofloxacin solution/ drops </strong><br>PACK Pharmaceuticals, LLC<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="aba05758-6dd1-4bf6-b1ec-1d79bdf2e8b2"></a><a name="section-1"></a><p></p>
<h1></h1>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Levofloxacin Ophthalmic Solution 0.5% </span></td></tr>
<tr class="Botrule Last"><td align="center"><span class="Bold">Sterile</span></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="fa1a5328-051c-40d9-aa31-6826e79ad18a"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION:</h1>
<p class="First">Levofloxacin Ophthalmic Solution 0.5% is a sterile
                            topical ophthalmic solution. Levofloxacin is a fluoroquinolone
                            antibacterial active against a broad spectrum of Gram-positive and
                            Gram-negative ocular pathogens. Levofloxacin is the pure
                            (-)-(s)-enantiomer of the racemic drug substance, ofloxacin. It is more
                            soluble in water neutral pH than ofloxacin.</p>
<table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span>Structural formula:</span></td></tr>
<tr><td align="center"><img alt="Levofloxacin Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f79d2ae4-ccfb-49ca-bf0e-e505f3477d30&amp;name=levofloxacin-figure-1-LevofloxacinStructuralFormula.jpg"></td></tr>
<tr><td align="center">Levofloxacin Hemihydrate</td></tr>
<tr class="Botrule Last"><td align="center">C<span class="Sub">18</span>H<span class="Sub">20</span>FN<span class="Sub">3</span>O<span class="Sub">4</span>   ½ H<span class="Sub">2</span>O Mol Wt 370.38</td></tr>
</tbody>
</table>
<p><span class="Bold"><span class="Emphasis">Chemical Name:</span></span>
                            (-)-(s)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido
                            [1,2,3-de]-1,4 benzoxazine-6-carboxylic acid hemihydrate. Levofloxacin
                            (hemihydrate) is a yellowish-white crystalline powder. Each mL of
                            Levofloxacin Ophthalmic Solution contains 5.12 mg of levofloxacin
                            hemihydrate equivalent to 5 mg levofloxacin.</p>
<p><span class="Bold"><span class="Emphasis">Contains: </span></span></p>
<p><span class="Bold"><span class="Emphasis">Active:</span></span> Levofloxacin 0.5% ( mg/mL); <span class="Bold"><span class="Emphasis">Preservative:</span></span> benzalkonium chloride 0.005%;</p>
<p><span class="Bold"><span class="Emphasis">Inactives:</span></span> sodium chloride and water for injection. May also contain
                            hydrochloric acid and/or sodium hydroxide to adjust pH. Levofloxacin
                            Ophthalmic Solution is isotonic and formulated at pH 6.5 with an
                            <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of approximately 300 mOsm/kg. Levofloxacin is a fluorinated
                            4-quinolone containing a six-member (pyridobenzoxazine) ring from
                            positions 1 to 8 of the basic ring structure. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="b0cf9ab1-79ef-480f-814f-bd1d691f6578"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="a877270f-04b5-46c3-aaee-6defee59faf1"></a><a name="section-4"></a><p></p>
<h1>Pharmacokinetics:</h1>
<p class="First">Levofloxacin concentration in plasma was measured in 15 healthy
                            adult volunteers at various time points during a 15 day course of
                            treatment with Levofloxacin Ophthalmic Solution. The mean levofloxacin
                            concentration in plasma 1 hour postdose, ranged from 0.86 ng/mL on Day 1
                            to 2.05 ng/mL on Day 15. The highest maximum mean levofloxacin
                            concentration of 2.5 ng/mL was measured on Day 4 following 2 days of
                            dosing every 2 hours for a total of 8 doses per day. Maximum mean
                            levofloxacin concentrations increased from 0.94 ng/mL on Day 1 to 2.15
                            ng/mL on Day 15, which is more than 1,000 times lower than those
                            reported after standard oral doses of levofloxacin. Levofloxacin
                            concentration in tears was measured in 30 healthy adult volunteers at
                            various time points following instillation of a single drop of
                            Levofloxacin Ophthalmic Solution. Mean levofloxacin concentrations in
                            tears ranged from 34.9 to 221.1 μg/mL during the 60-minute
                            period following the single dose. The mean tear concentrations measured
                            4 and 6 hours postdose were 17.0 and 6.6 μg/mL. The clinical
                            significance of these concentrations is unknown.</p>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="e3402de4-cf78-46a0-9871-1568bbf85238"></a><a name="section-5"></a><p></p>
<h1>Microbiology:</h1>
<p class="First">Levofloxacin is the L-isomer of the racemate, ofloxacin, a
                            quinolone antimicrobial agent. The antibacterial activity of ofloxacin
                            resides primarily in the L-isomer. The mechanism of action of
                            levofloxacin and other fluoroquinolone antimicrobials involves the
                            inhibition of bacterial topoisomerase IV and DNA gyrase (both of which
                            are type II topoismerases), enzymes required for DNA replication,
                            transcription, repair, and recombination. Levofloxacin has <span class="Italics"><span class="Emphasis">in vitro</span></span> activity against a wide range of Gram-negative and
                            Gram-positive microorganisms and is often bactericidal at concentrations
                            equal to or slightly greater than inhibitory concentrations.</p>
<p>Fluoroquinolones, including levofloxacin, differ in chemical
                            structure and mode of action from β-lactam antibiotics and
                            aminoglycosides, and therefore may be active against bacteria resistant
                            to β-lactam antibiotics and aminoglycosides. Additionally,
                            β-lactam antibiotics and aminoglycosides may be active against
                            bacteria resistant to levofloxacin. Resistance to levofloxacin due to
                            spontaneous mutation <span class="Italics"><span class="Emphasis">in vitro</span></span> is a rare occurrence (range: 10<span class="Sup">-9</span> to
                                10<span class="Sup">-10</span>). Levofloxacin has been shown to be active against
                            most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics"><span class="Emphasis">in vitro</span></span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS
                            AND USAGE section:</p>
<p><span class="Bold"><span class="Emphasis">AEROBIC GRAM-POSITIVE
                                    MICROORGANISMS</span></span></p>
<p>Corynebacterium species*</p>
<p><span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span></p>
<p><span class="Italics"><span class="Emphasis">Staphylococcus epidermidis</span></span></p>
<p><span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span></p>
<p><span class="Italics"><span class="Emphasis">Streptococcus</span></span> (Groups C/F)</p>
<p><span class="Italics"><span class="Emphasis">Streptococcus</span></span> (Group G)</p>
<p>Viridans group streptococci</p>
<p><span class="Bold"><span class="Emphasis">AEROBIC GRAM-NEGATIVE
                                    MICROORGANISMS</span></span></p>
<p><span class="Italics"><span class="Emphasis">Acinetobacter lwoffii*</span></span></p>
<p><span class="Italics"><span class="Emphasis">Haemophilus influenzae</span></span></p>
<p><span class="Italics"><span class="Emphasis">Serratia marcescens</span></span>*</p>
<p>*Efficacy for this organism was studied in fewer than 10
                            <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. The following <span class="Italics"><span class="Emphasis">in vitro</span></span> data are also available, but their clinical significance in
                            ophthalmic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> is unknown. The safety and effectiveness of
                            levofloxacin in treating ophthalmological <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these
                            microorganisms have not been established in adequate and well-controlled
                            trials. These organisms are considered susceptible when evaluated using
                            systemic breakpoints. However, a correlation between the <span class="Italics"><span class="Emphasis">in vitro</span></span> systemic breakpoint and ophthalmological efficacy has not
                            been established. The list of organisms is provided as guidance only in
                            assessing the potential treatment of conjunctival
                            <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p>Levofloxacin exhibits <span class="Italics"><span class="Emphasis">in vitro</span></span> minimal inhibitory concentrations (MICs) of 2μg/mL
                            or less (systemic susceptible breakpoint) against most
                            (≥90%) <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following ocular
                            pathogens:</p>
<p><span class="Bold"><span class="Emphasis">Aerobic gram-positive
                                    microorganisms</span></span></p>
<p><span class="Italics"><span class="Emphasis">Enterococcus faecalis</span></span></p>
<p><span class="Italics"><span class="Emphasis">Streptococcus agalactiae</span></span></p>
<p><span class="Italics"><span class="Emphasis">Staphylococcus saprophyticus</span></span></p>
<p><span class="Italics"><span class="Emphasis">Streptococcus pyogenes</span></span></p>
<p><span class="Bold"><span class="Emphasis">Aerobic gram-negative
                                    microorganisms</span></span></p>
<p><span class="Italics"><span class="Emphasis">Acinetobacter anitratus</span></span></p>
<p><span class="Italics"><span class="Emphasis">Legionella pneumophila</span></span></p>
<p><span class="Italics"><span class="Emphasis">Acinetobacter baumannii</span></span></p>
<p><span class="Italics"><span class="Emphasis">Moraxella catarrhalis</span></span></p>
<p><span class="Italics"><span class="Emphasis">Citrobacter diversusi</span></span></p>
<p><span class="Italics"><span class="Emphasis">Morganella morgqanii</span></span></p>
<p><span class="Italics"><span class="Emphasis">Citrobacter freudii</span></span></p>
<p><span class="Italics"><span class="Emphasis">Neisseria gonorrhoeae</span></span></p>
<p><span class="Italics"><span class="Emphasis">Enterobacter aerogenes</span></span></p>
<p><span class="Italics"><span class="Emphasis">Proteus mirabilis</span></span></p>
<p><span class="Italics"><span class="Emphasis">Enterobacter agglomerans</span></span></p>
<p><span class="Italics"><span class="Emphasis">Proteus vulgaris</span></span></p>
<p><span class="Italics"><span class="Emphasis">Enteroacter cloacae</span></span></p>
<p><span class="Italics"><span class="Emphasis">Providencia rettgeri</span></span></p>
<p><span class="Italics"><span class="Emphasis">Escherichia coli</span></span></p>
<p><span class="Italics"><span class="Emphasis">Providencia stuartii</span></span></p>
<p><span class="Italics"><span class="Emphasis">Haemophilus arainfluenzae</span></span></p>
<p><span class="Italics"><span class="Emphasis">Pseudomonas aeruginosa</span></span></p>
<p><span class="Italics"><span class="Emphasis">Klebsiella oxytoca</span></span></p>
<p><span class="Italics"><span class="Emphasis">Pseudomonas fluorescens</span></span></p>
<p><span class="Italics"><span class="Emphasis">Klebsiella
                                    pneumoniae </span></span> </p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="b7947323-cd7f-459f-bc37-1aca1ea89cf1"></a><a name="section-6"></a><p></p>
<h1>Clinical Studies:</h1>
<p class="First">In randomized, double-masked, multicenter controlled clinical
                            trial where patients were dosed for 5 days, Levofloxacin Ophthalmic
                            Solution demonstrated clinical cures in 79% of patients treated
                            for bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> on the final study visit day (day 6-10).
                            Microbial outcome for the same clinical trials demonstrated an
                            eradication rate for presumed pathogens of 90%.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="c0047360-bef3-41f3-8afe-4a44f7997d16"></a><a name="section-7"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Levofloxacin Ophthalmic Solution is indicated for the treatment
                            of bacterial <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the
                            following organisms:</p>
<p><span class="Bold"><span class="Emphasis">AEROBIC GRAM-POSITIVE
                                    MICROORGANISMS</span></span></p>
<p><span class="Italics"><span class="Emphasis">Corynebacterium species*</span></span></p>
<p><span class="Italics"><span class="Emphasis">Staphylococcus aureus</span></span></p>
<p><span class="Italics"><span class="Emphasis">Staphylococcus epidermidis</span></span></p>
<p><span class="Italics"><span class="Emphasis">Streptococcus pneumoniae</span></span></p>
<p><span class="Italics"><span class="Emphasis">Streptococcus</span></span> (Groups C/F)</p>
<p><span class="Italics"><span class="Emphasis">Streptococcus</span></span> (Group G)</p>
<p>Viridans group streptococci</p>
<p><span class="Bold"><span class="Emphasis">AEROBIC GRAM-NEGATIVE
                                    MICROORGANISMS</span></span></p>
<p><span class="Italics"><span class="Emphasis">Acinetobacter lwoffii*</span></span></p>
<p><span class="Italics"><span class="Emphasis">Haemophilus influenzae</span></span></p>
<p><span class="Italics"><span class="Emphasis">Serratia marcescens* </span></span></p>
<p>*Efficacy for this organism was studied in fewer than 10
                            <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="d6fc61f0-7673-4353-9af6-3c7d9687eaaf"></a><a name="section-8"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Levofloxacin Ophthalmic Solution is contraindicated in patients
                            with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to levofloxacin, to other quinolones,
                            or to any of the components of this medication.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="a1e6ce45-3ac7-44c8-b98e-255fb922b8fe"></a><a name="section-9"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">NOT FOR INJECTION. Levofloxacin Ophthalmic Solution should not be
                            injected subconjunctially, nor should it be introduced directly into the
                            anterior chamber of the eye.</p>
<p>In patients receiving systemic quinolones, serious and
                            occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been
                            reported, some following the first dose. Some reactions were accompanied
                            by <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> (including
                            laryngeal, pharyngeal or facial <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>), airway obstruction, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>,
                            <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to levofloxacin occurs,
                            discontinue the drug. Serious acute <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may
                            require immediate emergency treatment. Oxygen and airway management
                            should be administered as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="fa2daa74-c7a1-485e-8919-9ffa7a33b319"></a><a name="section-10"></a><p></p>
<h1>PRECAUTIONS</h1>
</div>
<div class="Section" data-sectionCode="34072-9">
<a name="e3ee52fe-4d82-4f95-a83d-249c5002c9a9"></a><a name="section-11"></a><p></p>
<h1>General</h1>
<p class="First">As with other anti-infectives, prolonged use may result in
                            overgrowth of non-susceptible organisms, including fungi. If
                            <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, discontinue use and institute alternative
                            therapy. Whenever clinical judgment dictates, the patient should be
                            examined with the aid of magnification, such as slitlamp biomicroscopy,
                            and where appropriate, fluorescein staining. Patients should be advised
                            not to wear contact lenses if they have signs and symptoms of bacterial
                            <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="fd2120dd-2598-4652-8315-c671cf5b02ce"></a><a name="section-12"></a><p></p>
<h1>Information for Patients</h1>
<p class="First">Avoid contaminating the applicator tip with material from the
                            eye, fingers or other source. Systemic quinolones have been associated
                            with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, even following a single dose.
                            Discontinue use immediately and contact your physician at the first sign
                            of a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="b064e975-c504-4673-8aeb-90dce32fb517"></a><a name="section-13"></a><p></p>
<h1>Drug Interactions:</h1>
<p class="First">Specific drug interaction studies have not been conducted with
                            Levofloxacin Ophthalmic Solution. However, the systemic administration
                            of some quinolones has been shown to elevate plasma concentrations of
                            theophylline, interfere with the metabolism of caffeine, and enhance the
                            effects of the oral anticoagulant warfarin and its derivatives, and has
                            been associated with transient elevations in serum creatinine in
                            patients receiving systemic cyclosporine concomitantly.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="ae7a2f53-e362-4f41-87cc-bd7fc3a544bd"></a><a name="section-14"></a><p></p>
<h1>Carcinogenesis, Mutagenesis, Impairment of Fertility:</h1>
<p class="First">In a long term carcinogenicity study in rats, levofloxacin
                            exhibited no carcinogenic or tumorigenic potential following daily
                            dietary administration; the highest dose (100 mg/kg/day) was 875 times
                            the highest recommended human ophthalmic dose. Levofloxacin was not
                            mutagenic in the following assays: Ames bacterial mutation assay (S.
                            typhimurium and E. coli), CHO/HGPRT forward mutation assay, mouse
                            micronucleus test, mouse dominant lethal test, rat unscheduled DNA
                            synthesis assay, and the <span class="Italics"><span class="Emphasis">in vivo</span></span> mouse sister chromatid exchange assay. It was positive in the
                                <span class="Italics"><span class="Emphasis">in vitro</span></span> chromosomal aberration (CHL cell line) and <span class="Italics"><span class="Emphasis">in vitro</span></span> sister chromatid exchange (CHL/IU cell line) assays.
                            Levofloxacin caused no impairment of fertility or reproduction in rats
                            at oral doses as high as 360 mg/kg/day, corresponding to 3,150 times the
                            highest recommended human ophthalmic dose. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="e459c015-0971-4458-a6a8-f41cdba4e77e"></a><a name="section-15"></a><p></p>
<h1>Pregnancy: Teratogenic Effects. Pregnancy Category C</h1>
<p class="First">Levofloxacin at oral doses of 810 mg/kg/day in rats, which
                            corresponds to approximately 7,000 times the highest recommended human
                            ophthalmic dose, caused decreased fetal body weight and increased fetal
                            mortality. No teratogenic effect was observed when rabbits were dosed
                            orally as high as 50 mg/kg/day, which corresponds to approximately 400
                            times the highest recommended maximum human ophthalmic dose, or when
                            dosed intravenously as high as 25 mg/kg/day, corresponding to
                            approximately 200 times the highest recommended human ophthalmic dose.
                            There are, however, no adequate and well-controlled studies in pregnant
                            woman. Levofloxacin should be used during pregnancy only if the
                            potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="a0801702-052b-40dc-b00e-32b2751098cd"></a><a name="section-16"></a><p></p>
<h1>Nursing Mothers:</h1>
<p class="First">Levofloxacin has not been measured in human milk. Based upon data
                            from ofloxacin, it can be presumed that levofloxacin is excreted in
                            human milk. Caution should be exercised when Levofloxacin Ophthalmic
                            Solution is administered to a nursing mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="fb1af3a6-46ad-4381-a905-c4b8f3103509"></a><a name="section-17"></a><p></p>
<h1>Pediatric Use:</h1>
<p class="First">Safety and effectiveness in infants below the age of one year
                            have not been established. Oral administration of quinolones has been
                            shown to cause <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span> in immature animals. There is no evidence
                            that the ophthalmic administration of levofloxacin has any effect on
                            weight bearing joints.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ced0ba70-db57-432a-aaf3-f7df1a710b15"></a><a name="section-18"></a><p></p>
<h1>Geriatric Use:</h1>
<p class="First">No overall differences in safety or effectiveness have been
                            observed between elderly and other adult patients.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="d1a416f8-2770-462f-9cfe-afdd5856c6ed"></a><a name="section-19"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently reported adverse events in the overall study
                            populations were transient decreased vision, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, foreign body
                            sensation, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, transient ocular burning, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> or
                            <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> and <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>. These events occurred in
                            approximately 1-3% of patients. Other reported reactions
                            occurring in less than 1% of patients included allergic
                            reactions, lid <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, ocular dryness and <span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">ocular itching</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f18268e5-e6de-45e6-9aef-0924ba0b3c1a"></a><a name="section-20"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold"><span class="Emphasis">Days 1 and 2:</span></span></p>
<p>Instill one to two drops in the affected eye(s) every 2 hours
                            while awake, up to 8 times per day.</p>
<p><span class="Bold"><span class="Emphasis">Days 3 through 7:</span></span></p>
<p>Instill one to two drops in the affected eye(s) every 4 hours
                            while awake, up to 4 times per day.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="a3c61279-f780-4539-a347-bb3bd1f6f4a3"></a><a name="section-21"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Levofloxacin Ophthalmic Solution 0.5% is supplied in a
                            natural, low density polyethylene bottle with a controlled dropper tip
                            and a tan, high density polyethylene cap in the following
                            size:</p>
<p>Bottles of 5 mL    NDC
                            16571-150-50 <br>Store at 20°-25°C
                            (68°-77°F) </p>
<p><span class="Bold"><span class="Emphasis">Rx Only</span></span></p>
<p>Manufactured in India for:<br>
                         Nexus Pharmaceuticals Inc.,<br>
                         Vernon Hills, IL 60061.</p>
<p>Distributed by:<br>
                         Pack Pharmaceuticals,<br>
                         LLC, Buffalo Grove, IL 60089.</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="dfc6647d-09ff-472b-a9c2-95e6191cb58f"></a><a name="section-22"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL PRINCIPAL DISPLAY PANEL
                                    - Levofloxacin Solution 5 ml Carton Label</span></span></p>
<p>NDC  16571-150-50</p>
<p><span class="Bold"><span class="Emphasis">PACK Pharmaceuticals, LLC</span></span></p>
<p><span class="Bold"><span class="Emphasis">LEVOFLOXACIN OPHTHALMIC
                                    SOLUTION</span></span></p>
<p><span class="Bold"><span class="Emphasis">0.5%</span></span></p>
<p>FOR TOPICAL APPLICATION IN THE EYE</p>
<p>Rx
                            only                                        (5
                            mL) Sterile</p>
<p><img alt="Levofloxacin Ophthalmic 5 mL Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f79d2ae4-ccfb-49ca-bf0e-e505f3477d30&amp;name=levofloxacin-figure-2-Levofloxacin_Ophthalmic_5_mL_Carton.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LEVOFLOXACIN 		
					</strong><br><span class="contentTableReg">levofloxacin solution/ drops</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:16571-150</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>LEVOFLOXACIN</strong> (LEVOFLOXACIN) </td>
<td class="formItem">LEVOFLOXACIN</td>
<td class="formItem">5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>BENZALKONIUM CHLORIDE</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HYDROCHLORIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:16571-150-50</td>
<td class="formItem">48  in 1 CASE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA077700</td>
<td class="formItem">12/20/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PACK Pharmaceuticals, LLC
							(614823875)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>Nexus Pharmaceuticals Inc (620714787)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Indoco Remedies Ltd.</td>
<td class="formItem"></td>
<td class="formItem">915851870</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c9ef1bfa-00ae-4847-9588-97215974bad8</div>
<div>Set id: f79d2ae4-ccfb-49ca-bf0e-e505f3477d30</div>
<div>Version: 3</div>
<div>Effective Time: 20110504</div>
</div>
</div> <div class="DistributorName">PACK Pharmaceuticals, LLC</div></p>
</body></html>
